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Introduction: This Phase I trial aimed to determine the maximum-
tolerated-dose of erlotinib administered with two standard chemo-
radiotherapy regimens for non-small cell lung cancer.
Methods: Unresectable stage III non-small cell lung cancer patients
were enrolled in this 2-arm dose-escalation study. Erlotinib, given
only during chemoradiotherapy, was escalated from 50 to 150 mg/d
in 3 to 6 patient cohorts. Arm A: erlotinib with cisplatin (50 mg/m2
IV days 1, 8, 29, 36), etoposide (50 mg/m2 IV days 1–5, 29–33) and
chest radiotherapy (66 Gy, 2 Gy/d) followed by docetaxel (75
mg/m2 IV Q21 d) for 3 cycles. Arm B: induction carboplatin
(AUC 6) and paclitaxel (200 mg/m2) for two 21-d cycles then
radiotherapy with erlotinib, carboplatin (AUC  2/wk) and
paclitaxel (50 mg/m2/wk).
Results: Seventeen patients were treated in each arm. Patient char-
acteristics: performance status 0 to 24 patients, 1 to 10 patients,
median age 63 years, adenocarcinoma 21% and female 14 patients.
Dose-escalation of erlotinib to 150 mg/d was possible on both
chemoradiotherapy regimens. Grade 3/4 leukopenia and neutropenia
were predominant toxicities in both arms. Grade 3 chemoradiother-
apy toxicities in arm A were esophagitis (3 patients), vomiting (1),
ototoxicity (1), diarrhea (2), dehydration (3), pneumonitis (1); and
arm B was esophagitis (6). Seven patients (21%) developed rash (all
grade 1/2). Median survival times for patients on Arm A and B were
10.2 and 13.7 months, respectively. Three-year overall survival in
patients with and without rash were 53% and 10%, respectively
(log-rank P  0.0807). Epidermal growth factor receptor IHC or
FISH positive patients showed no significant overall survival
difference.
Conclusion: Addition of standard-dose erlotinib to chemoradiother-
apy is feasible without evident increase in toxicities. However, the
survival data are disappointing in this unselected patient population
and does not support further investigation of this approach.
Key Words: Non-small cell lung cancer, Chemoradiotherapy, Mul-
timodality therapy, Erlotinib, Epidermal-growth factor inhibitor.
(J Thorac Oncol. 2008;3: 1003–1011)
Prognosis of patients with unresectable stage III nonsmallcell lung cancer (NSCLC) has improved over the past two
decades with concurrent chemoradiotherapy.1–4 Attempts to
further improve the outcome of unresectable stage III NSCLC
with the use of induction or consolidation chemotherapy have
not been successful.5,6 The pressing need for more effective
combined modalitiy-therapies in NSCLC lead us to explore
targeting the epidermal growth factor receptor (EGFR).
EGFR overexpression occurs in approximately 60% of
NSCLC and correlates with higher stage and worse prognosis.7,8
There is a positive correlation between EGFR expression and
tumor radioresistance.9–12 Furthermore, the degree of radioresis-
tance correlates with the magnitude of EGFR overexpression.9
In addition, radiation damage results in activation of EGFR and
subsequently augments cell survival and repopulation.13 By
inhibiting EGFR activation, tumor cells may become more
radiosensitive.14–16 This hypothesis is validated in the treatment
of head and neck cancer with concurrent cetuximab and radio-
therapy.17
Based on this rationale, we performed a two-arm phase I
study to incorporate erlotinib into two frequently used chemo-
radiotherapy regimens (SWOG950418 and CALGB398015) for
unresectable Stage III NSCLC. Erlotinib, an EGFR tyrosine
kinase inhibitor (TKI) results in single-agent response rates of
approximately 10% in unselected metastatic NSCLC patient
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populations but demonstrates higher activity in selected clinical
or molecular patient subsets.19 We hypothesized that the addi-
tion of erlotinib to concomitant chemoradiotherapy could further
increase radio- and/or chemotherapy sensitivity of tumor cells
and result in higher locoregional and systemic control rates.
METHODS
This study aimed to determine the maximum tolerated
dose (MTD) and dose-limiting toxicity (DLT) of erlotinib
administered with chest radiotherapy and concomitant cispla-
tin-etoposide (Arm A); and carboplatin-paclitaxel (Arm B)
for unresectable stage III NSCLC.
Eligibility Criteria
Untreated patients with pathologically confirmed, un-
resectable, or inoperable Stage III NSCLC were eligible.
Patients with malignant pleural effusions were ineligible. All
patients were over 18 year of age, had an Eastern Cooperative
Oncology Group performance status of 0 to 1 and adequate
hematological (white blood cell count 3000/L, absolute
neutrophil count 1500/L, platelet count 100,000/L),
hepatic (bilirubin within upper limit of normal (ULN), serum
transaminases  1.5  ULN, alkaline phosphotase  2.5 
ULN) and renal (creatinine clearance 50 mL/min) function.
Patients were required to have at least one measurable lesion
by chest x-ray, computerized tomography or magnetic reso-
nance imaging.
Treatment Regimen
The treatment schema is shown in Figure 1. Patients
received erlotinib only during concurrent chemoradiotherapy.
Therapy on arm A, administered as in SWOG9504,18 con-
sisted of concurrent radiotherapy (66 Gy, 5 fractions/wk over
7 wk) with concurrent cisplatin 50 mg/m2 on days 1, 8, 29,
and 36 and etoposide 50 mg/m2 daily on days 1 to 5 and 29
to 33. After completion of concurrent chemoradiotherapy,
consolidation docetaxel 75 mg/m2 every 3 weeks for 3 cycles
(days 50, 71, and 92) was administered.
Therapy on arm B was administered as in CALGB39801.5
Treatment consisted of induction chemotherapy with paclitaxel
200 mg/m2 and carboplatin AUC 6 on days 1 and 21. Concur-
rent chemoradiotherapy consisted of weekly paclitaxel 50
mg/m2 and carboplatin AUC 2 on days 43, 50, 57, 64, 71, 78,
and 85 with concurrent chest radiotherapy beginning on day 43
to a total of 66 Gy. The target volumes of irradiation were
defined prior to the administration of induction chemotherapy.
Radiation therapy was given using photon beams with
energy between 4 and 25 MV. Clinical target volume in-
cluded the gross target volume, potential occult disease, the
ipsilateral hilum, and mediastinum. Clinical target volume
was treated with an initial 44 Gy at 2 Gy/fraction. Boost
volume included the gross tumor volume, ipsilateral hilum,
and ipsilateral mediastinum; and was treated to 22 Gy at 2
Gy/fraction. No corrections for lung or bone attenuation were
made. Maximum dose to any point in the spinal cord was
49 Gy. Two- and three-dimensional treatment planning were
allowed.
Supportive Care
Prophylactic use of granulocyte colony stimulating fac-
tor was not permitted. Erythropoietin was recommended for
hemoglobin below 10 g/dL. Carafate and fluconazole was
added during chemoradiotherapy as needed. Topical anti-
inflammatory acne therapy and/or oral antibiotics were used
to treat rash.20
Toxicity Evaluation and Dose Escalation
Patients were assigned to a dose level, alternating
between arm A or arm B (Fig. 2). On both study arms the
dose levels of erlotinib started at 50 mg orally daily (level I),
and escalated to 100 mg daily (level II) and 150 mg daily
(level III).
Patients were evaluated weekly for toxicity using the NCI
Common Toxicity Criteria 2.0. The trial was initially written to
define DLT as the occurrence of grade 4 neutropenia. Since
neutropenia is the predominant toxicity encountered during
standard concomitant chemoradiotherapy, an amendment to ex-
clude neutropenia as a DLT was approved midway during the
accrual for dose level 1. DLT in this trial was defined as: Grade
4 thrombocytopenia, or need for platelet transfusion, grade 4
esophagitis, grade 4 vomiting despite maximal antiemetic sup-
port, grade 3 or greater despite antidiarrheal support, and any
toxicity grade 3 or greater exceeding 7 days. Anemia, nausea,
fatigue and alopecia were not considered DLTs.
A minimum of three assessable patients were entered at
each dose level. Erlotinib was started at dose level I (50 mg).
FIGURE 1. Treatment schema of Arms A and
Arm B. (C–cisplatin, CB–carboplatin, D–docetaxel,
E–Etoposide, P–Paclitaxel).
Choong et al. Journal of Thoracic Oncology • Volume 3, Number 9, September 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1004
If DLT developed, the dose level was expanded to include six
patients. Dose escalation continued until greater than one
third of patients treated at a given dose level developed DLT.
Once the MTD was determined, up to an additional six
patients were to be tested at the determined MTD for each
sequence.
Response Evaluation and Statistical
Considerations
Arm A and B were evaluated separately to determine the
MTD of each regimen. Response to treatment was assessed in all
patients. Best clinical response to treatment with erlotinib and
chemoradiotherapy was determined using the Response Evalu-
ation Criteria in Solid Tumors criteria. Response evaluation for
arm A was performed after concurrent chemoradiotherapy and
after consolidation chemotherapy. In arm B, response evaluation
was performed after induction chemotherapy and after concur-
rent chemoradiotherapy. Patients who were not evaluable, died
early from any cause, or withdrew from the study were consid-
ered as failing to respond to the treatment, and were classified as
disease progression.
Immunohistochemistry for Epidermal Growth
Factor Receptor
Samples of tissue sections from the primary tumors were
identified and cut in 5 m sections onto positively charged
slides. The tissue sections were deparaffinized in xylene and
hydrated with alcohol before being placed in 3% H2O2/methanol
blocking solution to quench endogenous peroxidase activity
followed by subsequent antigen unmasking. Nonspecific bind-
ing was reduced by incubating the slides in a protein blocking
solution for 20 min. Incubation with the primary antibodies was
done with the monoclonal anti-EGFR antibody clone 31G7
(Invitrogen/Zymed, Carlsbad, CA) with a 1:100 dilution. After
washing with TBS, the slides were incubated for 30 min at room
temperature with goat anti-rabbit IgG conjugated to a horserad-
ish peroxidase–labeled polymer (Envision System, Carpinteria,
CA). Reactions were developed with 3,3-diaminobenzidine
chromogen and counterstained with hematoxylin. Appropriate
negative controls for the immunostaining were prepared by
omitting the primary antibody step and substituting it with
nonimmune rabbit serum.
All of the slides were reviewed by an independent pathol-
ogist and standard scoring was performed. For each case, an
average number of 1500 cells per section was evaluated utilizing
a semi-quantitative grading system based on 4 stages (0, no
staining; 1, staining in 1–10% of considered cells; 2, stain-
ing in 11–25% of considered cells; 3, staining in 25% of
considered cells).21 Tumors with 2 or 3 staining were con-
sidered EGFR positive on IHC.
Fluorescent In Situ Hybridization
Fluorescence in situ hybridization for detection of
EGFR gene amplification was performed on formalin-fixed
paraffin-embedded tissue sections adjacent to those analyzed
by IHC using the Vysis Inc. LSI® Locus Specific Identifier
DNA Probes (Vysis/Abbott Inc., Des Planes, IL), which is a
hybridization mixture of a EGFR probe labeled with Spec-
trumOrange, and a chromosome 7 enumeration probe CEP7,
labeled with SpectrumGreen. Slides were pretreated using the
Vysis/Abbots Inc. Paraffin Pretreatment Kit and Post-Hybrid-
ization Rapid Wash LSI Protocols. Briefly, slides were baked
at 70°C overnight, deparaffinized in series of xylenes, dehy-
drated in 100% ethanol. After incubation in sodium chloride,
slides were pretreated in sodium thiocyanate (1 M NaSCN,
80°C for 30 min), washed in standard saline citrate buffer
(2  SSC) and processed for digestion with Pepsin (Sigma,
2300 U/mg, 0.5 mg/mL in 0.9% NaCl, pH  1.5). Slides
were fixed in 10% buffered formalin for 10 min, washed in
2 SSC, and denatured in 70% formamide at 75°C for 5 min
and dehydrated in ethanol series. Probe mixture was diluted
in t-DenHyb-2 hybridization buffer (InSitus Biotechnologies,
Albuquerque, NM, USA) as described by the manufacturer,
denatured and applied to the slide. Hybridization was con-
ducted in a humid chamber at 37°C overnight. Slides were
immersed in 2  SSC/0.1% NP40 at room temperature for 2
minutes followed by wash in 0.4  SSC/0.3% NP40 at 73°C
for 2 min. For visualizing the hybridization, DAPI II coun-
terstain by Vysis was applied.
In each tumor sample an average of 80 (30–200) well-
defined malignant nuclei were scored. The absolute number of
EGFR signals, the ratio of EGFR signals to CEP7 signals and
the percentage of cells with given copy number of each signal
per cell were recorded. Tumors with a EGFR:CEP7 signal ratio
2 were considered nonamplified, whereas those with a ratio of
2 or greater (or15 copies of EGFR per cells in 10% of cells)
were considered amplified. “Low amplification” was defined as
ratio of 2.0 to 3.0 and “high amplification” a ratio of 3. The
alterations in EGFR signals due to alterations in chromosome 7
copy number were classified as described previously.7,22 Briefly,
disomy, 2 gene copies in more than 90% of cells; trisomy, 3
gene copies in10% of cells; low polysomy,4 gene copies in
10% but less than 40%; high polysomy, 4 gene copies in
40%. Fluorescent in situ hybridization (FISH) positivity was
defined by the high number of the copies of EGFR (amplifica-
tion or high polysomy).7,22,23
RESULTS
Patient Characteristics
Between July 2002 and March 2006, 34 patients were
enrolled (Table 1). There were 14 women and 20 men with a
median age of 63 years (39–78 years). All patients were
FIGURE 2. Dose escalation schema for Arms A and B.
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either current or former smokers. Ten patients (24%) had
Stage IIIA disease while 24 (71%) had Stage IIIB disease.
Histologic subtypes were: poorly differentiated 47%, squa-
mous cell carcinoma 29%, adenocarcinomas 21% and large
cell carcinoma 3%.
Toxicity
Chemoradiotherapy Toxicity in Arm A
Of four evaluable patients in dose level 1, grade 3/4
neutropenia occurred in three patients (75%), and grade 3
FIGURE 3. Kaplan-Meier
curves for A, overall survival
in all patients; B, Progres-
sion-free survival in all pa-
tients according to treat-
ment arm; C, overall survival
in all patients according to
treatment arm (Arm A 
SWOG, Arm B  CALGB);
D, Progression-free survival
in all patients according to
treatment arm; E, Overall
survival according to ap-
pearance of rash; F, Progres-
sion-free survival according
to appearance of rash; G,
Overall survival according to
EGFR immunohistochemistry
or EGFR increased gene
copy number/amplification
status; H, Progression-free
survival according to EGFR
immunohistochemistry or
EGFR increased gene copy
number/amplification status.
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esophagitis in two patients (Table 2). One patient (25%)
developed grade 3 pneumonitis 5 weeks into chemoradiother-
apy and improved with corticosteroids.
Dose level 2 was well tolerated without DLT. One
patient in dose level 2 died just prior to starting consolidation
chemotherapy from a ruptured abdominal aortic aneurysm
that was unrelated to the therapy.
No DLTs were observed in the first three patients in
dose level 3. This cohort was subsequently expanded to nine
patients. As in previous dose levels, neutropenia was the most
common severe hematologic toxicity. Fatigue, esophagitis,
mucositis, neuropathy and diarrhea were the most common
nonhematologic toxicities. Grade 3 hearing loss was the only
DLT observed. It was at this dose level that rash was noted in
three patients (33%). Two patients were females and, all three
were poorly differentiated carcinomas. Grade 3 dehydration
occurred in three patients but improved rapidly with intrave-
nous hydration. Grade 3 diarrhea occurred in one patient and
improved with antidiarrheal therapy.
The MTD of treatment arm A was erlotinib 150 mg. With
exception of neutropenia and leucopenia noted early in the trial,
the only DLTs observed in this arm were hearing loss (1 patient)
and pneumonitis (1 patient). Commonly observed grade 3/4
toxicities were esophagitis (3 patients), leucopenia (9 patients),
neutropenia (8 patients), and thrombocytopenia (5 patients).
Chemoradiotherapy Toxicity in Arm B
In the five patients treated in dose level 1, grade 4
neutropenia was encountered in one patient (20%). This patient
also experienced grade 3 leucopenia and thrombocytopenia.
There were no other grade 3/4 toxicities observed in dose level
1. In dose level 2, one patient experienced grade 3 neutropenia; TA
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TABLE 1. Patient Demographics
n 34
Median age 63 yr 39.1–78.2 yr
Sex
Male 20 59%
Female 14 41%
Race
Caucasian 24 71%
African-American 10 29%
Performance status
0 24 71%
1 10 29%
Smoking status
Current smoker 10 29%
Ex-smoker 24 71%
Stage
IIIA 10 29%
IIIB 24 71%
Histology
Poorly differentiated 16 47%
Squamous cell carcinoma 10 29%
Adenocarcinoma 7 21%
Large cell carcinoma 1 3%
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all other hematologic toxicities were mild. Two patients (67%)
in this dose level experienced grade 3 esophagitis.
In dose level 3, no DLTs were observed in the first
three patients and this cohort was expanded to seven patients.
At this dose level, grade 3/4 neutropenia remained the pre-
dominant hematologic toxicity. Grade 3 esophagitis occurred
in four patients.
The MTD of treatment arm B was erlotinib 150 mg.
The only DLT observed was in one patient who developed
grade 4 thrombocytopenia. Commonly observed grade 3/4
toxicities were esophagitis (6 patients), and neutropenia (3
patients). Rash was observed in four patients (2 in dose level
1, and 1 each in dose levels 2 and 3). There were two female
patients who developed rash and two patients each had poorly
differentiated carcinoma and squamous cell carcinoma.
Toxicity from Chemotherapy
The maximum toxicity grades during consolidation
(Arm A) and induction (Arm B) chemotherapy are listed in
Table 3. Five patients did not receive consolidation docetaxel
(died of an aortic aneurysm rupture after concurrent chemo-
radiotherapy–1 patient, refusal of further therapy after che-
moradiotherapy–4 patients). Consolidation docetaxel was as-
sociated with grade 3/4 leukopenia (3 patients/4 patients).
Induction carboplatin-paclitaxel was well tolerated with ex-
pected rates of leukopenia, and thrombocytopenia. One pa-
tient died of a myocardial infarct and another patient devel-
oped grade 4 fatigue after induction chemotherapy.
Response Evaluation
Response to therapy was determined on an intention-to-
treat basis for all patients. In Arm A (n  17), partial response
was achieved in 11 patients for a 65% overall response rate.
Stable disease and progressive disease occurred in two (12%)
and four patients (24%), respectively. In Arm B (n  17), the
complete and partial response rates were 6% (1 patient) and 53%
(9 patients), respectively, for an overall response rate of 59%.
Stable disease and progressive disease occurred in two (12%)
and five patients (29%), respectively.
Sites of Failure
Relapse occurred in 21 patients. Local relapse occurred
in two patients (18%) in Arm A, and four patients (40%) in
Arm B. Distant relapse occurred in five patients (45%) in
Arm A and one patient (10%) in Arm B. Simultaneous local
and distant relapse occurred in four (36%) and three patients
(30%) in Arm A and B, respectively. Two patients in Arm B
had disease recurrence but their site of relapse was not
documented.
Survival
The median follow-up was 11.1 month (1–61 months),
seven patients were still alive. The intention-to-treat 12-, 24-,
and 36-month overall survivals were 50%, 25%, and 16%,
respectively and median survival was 11 months (Fig. 3A).
Median progression-free survival for the study was 9 months
(Fig. 3B). Intention-to-treat median survival for Arm A was
11 months and Arm B 15 months (Fig. 3C). The overall
survival for Arms A and B at 36 months, respectively were
20% and 16% (log-rank P  0.8979). The progression-free
survival at 36 months for Arm A was 13% and Arm B 15%
(log-rank P  0.9168) (Fig. 3D).
The median survival for patients who did not develop a
rash with erlotinib (n  24) was 10 months while the median
survival for patients who had rash of any grade (n  7) was
not reached (Fig. 3E). The overall survival between the
patients with rash and those without at 36 months were 53%
and 10%, respectively. This difference had a trend towards
improved outcome among patients who had a rash (log-rank
P  0.0807).
EGFR Status and Clinical Outcome Evaluation
Eighteen out of 22 available pathology samples (82%)
were successfully tested for EGFR IHC. Ten patients (56%)
had high EGFR staining. Twenty out of 22 pathology samples
(91%) were available and successfully tested for EGFR
FISH. While EGFR amplification was not observed, high
polysomy in five tumors (25%) accounted for FISH positivity
in this group. Three tumors demonstrated high EGFR staining
and FISH positivity.
Both EGFR FISH and IHC results were available in
eighteen patients. Three patients who were FISH positive also
had high EGFR expression by IHC, while eight patients who
were FISH negative had low EGFR expression. The concor-
dance rate between EGFR FISH and IHC was 61%.
Analysis of patients whose tumors either EGFR IHC or
FISH positive showed no significant overall survival differ-
ence over those who were negative for both (Fig. 3G). In
addition there was no significant difference between the two
groups in terms of progression-free survival or time to pro-
gression (Fig. 3H). In the seven patients who developed
acneiform rash, tumor tissue was available in five patients.
Three out of the 5 patients (60%) were found to have either
EGFR IHC or FISH positive tumors.
DISCUSSION
EGFR inhibitors play a significant role in the manage-
ment of metastatic NSCLC. EGFR-TKIs and anti-EGFR
TABLE 3. Toxicities Related to Consolidation Docetaxel (Arm A) and Induction Carboplatin-Paclitaxel (Arm B)
Hemoglobin Leucopenia Neutrpenia Platelets Anorexia Fatigue Nausea Vomiting Diarrhea Neuropathy
Grade 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4
Arm A
(n  12)
10(83%) 5(42%) 7(58%) 5(42%) 7(58%) 2(17%) 4(33%) 10(83%) 2(17%) 1(8%) 1(8%) 1(8%)
Arm B
(n  17)
9(53%) 5(29%) 1(6%) 2(12%) 6(35%) 2(12%) 1(6%) 4(24%) 11(65%) 1(6%) 5(29%) 1(6%) 2(12%) 5(29%)
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monoclonal antibodies are active in NSCLC.19,24 Laboratory
and clinical evidence supports the hypothesis that EGFR inhib-
itors may enhance radiosensitization.9–13,17 Combining EGFR
inhibition and concurrent chemoradiotherapy is of theoretical
interest since EGFR inhibition may result in increased tumor
radiosensitivity via mechanisms different from those of chemo-
therapy.
In this study, we sought to investigate the tolerability
and safety of erlotinib when combined with concurrent che-
moradiotherapy. Erlotinib was well tolerated at 150 mg daily
during concurrent chemoradiotherapy with the two com-
monly used regimens. We did not observe increased rates of
in-field dermatitis or radiation pneumonitis.
In this small trial, the response rate in both arms is
approximately 60% and appears similar to the response rates
achieved by the standard chemoradiotherapy regimens. The
median survival in Arm A and Arm B were 10.2 and 13.7
months, respectively. The median survival in Arm B was
similar as reported for CALGB 39801 study.5 The median
survival of Arm A was disappointing when compared with
reports on this regimen by SWOG or the Hoosier Oncology
Group trials.6,18
There may be several reasons for this difference. Inter-
trial comparisons have to be interpreted with caution and, the
small number and heterogenous population of our patients
must be taken into account. Nevertheless, a positive clinical
signal supporting the hypothesis of a benefit from the addition
of erlotinib to chemoradiotherapy using either base regimen
is not apparent in this trial.
Clinical predictors of response to EGFR TKIs—female,
East Asian race, adenocarcinoma histology and nonsmokers,
were not well represented in our study. We did, however,
observe that patients who developed an acneiform rash had a
trend towards improved survival. Skin rash developed in only
seven patients (21%) but in these patients, one attained a
complete response, four had partial responses, and one had
stable disease. This observation suggests an EGFR inhibition
effect and is consistent with other erlotinib studies in lung,19,25
head and neck,26 ovarian27 and pancreatic cancer28 demonstrat-
ing an association between response and survival with the
development of a rash and its severity. Interestingly, the inci-
dence of rash in our subjects is low compared with other studies
where rash occurred between 60 and 75% of subjects.19,29 The
occurrence of erlotinib-associated rash is related to the maxi-
mum concentration and AUC of erlotinib attained in patients.
There is a wide interindividual pharmacokinetic variability of
erlotinib which may in part be related to EGFR intron 1 poly-
morphism and the drug transporter, ATP-binding cassette G2
(ABCG2).30 The low incidence of rash in our subjects may
reflect our limited patient population.
In line with the findings of the BR21 study, we ob-
served that patients who had high EGFR expression or copy
numbers tended to also develop a rash and respond to ther-
apy.23 Furthermore, the BR21 study showed that patients with
high EGFR gene copy numbers also had a higher incidence of
rash and increased rash severity.31 Despite the improved
tumor response in our patients who have positive clinical and
molecular predictors of response, the improved response rate
did not translate into a survival benefit.
EGFR mutation analysis was not performed in our
study. When the trial was designed, it was not mandatory for
tumor tissue to be banked and sites were given the option to
collect three slices of paraffin-embedded tumor tissue. For
most of our patients the diagnosis of stage III NSCLC was
made on fine-needle aspiration where tumor blocks were not
made. This precluded us from obtaining an adequate sample
size to perform mutational analyses. However, the presence
of EGFR mutations has been predictive of tumor response to
erlotinib monotherapy,32 and Ready et al reported a statistical
trend between EGFR mutation status and survival when
gefitinib was delivered concurrently with radiotherapy.33
The poorer survival in our study may be attributed to
the presence of k-ras mutations which render tumors insen-
sitive to EGFR-TKIs.34 Although this postulation cannot be
tested definitively, our study patients are all current or former
smokers, which k-ras mutations are commonly associated.35
Furthermore, analysis of the TRIBUTE study showed that
patients with k-ras mutations had significantly shorter sur-
vival when treated with chemotherapy and erlotinib, suggest-
ing a possible detrimental effect of erlotinib in patients
harboring such mutations.36
The CALGB trial by Ready et al may have relevance to
our study.33 The trial administered induction carboplatin-pacli-
taxel followed by concurrent gefitinib, carboplatin, paclitaxel
and radiotherapy to “good-risk” patients (less than 5% weight
loss and performance status 0–1) and achieved a median sur-
vival of 12 months. However, in “poor-risk” patients, who
received induction carboplatin-paclitaxel followed by concur-
rent radiation therapy and gefitinib daily, an 18-month median
survival and 1-year survival of 60% was achieved. This differ-
ence in outcome suggests a possible antagonist effect of between
chemotherapy and gefitinib during chemoradiotherapy. Such an
effect may be responsible for the poor outcome in our trial and
in the trials evaluating EGFR-TKIs with chemotherapy.29,37–39
This finding is also supported by preclinical data demonstrat-
ing schedule-dependant interaction between cytotoxic che-
motherapy and EGFR-TKIs.40–43 It is hypothesized that con-
tinuous exposure to EGFR-TKIs results in G1 phase arrest,
and therefore reducing cell cycle phase-dependent activity of
cytotoxic chemotherapy.42–44 This effect preferentially af-
fects wild-type EGFR.43 Similarly, the SWOG 0023 which
randomized patients after concurrent chemoradiotherapy and
consolidation docetaxel to either maintenance placebo or
gefitinib, showed a worse survival in the gefitinib arm. There
have been numerous postulated reasons but they remain
unclear pending the molecular analysis of the pathology
samples.
EGFR-TKIs are standard second-line treatment for
NSCLC. Early trials determined that EGFR-TKIs do not im-
prove outcome when combined with chemotherapy. EGFR-
TKIs have not been explored with radiotherapy until recently.
This is the first study investigating concurrent administration of
erlotinib at its recommended single agent dose with chemora-
diotherapy. This approach was well tolerated. However, the
response rates and overall survivals observed in our small trial
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do not support further investigation of erlotinib with concurrent
chemoradiotherapy in an unselected population despite its tol-
erability. We did not find molecular parameters associated with
a favorable outcome. We did, however, observe that patients
who developed a rash appeared to have better outcomes with the
addition of erlotinib. This finding suggests that there may be
specific patient subsets that could benefit from the addition of
erlotinib to chemoradiotherapy and could be targeted in future
studies.
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